Here’s what you need to know.
1. The company plans to launch its product across the European Union in the coming year.
2. The test is marketed as having “the potential to reduce colonoscopies by up to 25 percent while maintaining almost 97 percent detection of colorectal cancer when combined with the fecal immunochemical test score.”
3. The test is the first VolitionRx plans to bring to market.
More articles on gastroenterology/endoscopy:
Dr. Theresa Ruddy joins Oswego Health: 4 notes
5 most read GI/endoscopy stories — Dec. 26 to Dec. 30, 2016
GI leader to know: Dr. Michael Brody of Cary Gastroenterology Associates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
